{"id":"oteseconazole-vt-1161","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the CYP51 enzyme, oteseconazole prevents the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This leads to accumulation of toxic sterol precursors and membrane destabilization, ultimately causing fungal cell death. The drug is designed to have improved selectivity for fungal CYP51 over human cytochrome P450 enzymes compared to earlier azole antifungals.","oneSentence":"Oteseconazole is a selective inhibitor of fungal lanosterol 14α-demethylase (CYP51) that disrupts ergosterol synthesis in fungal cell membranes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:02.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vulvovaginal candidiasis"},{"name":"Oral candidiasis"}]},"trialDetails":[{"nctId":"NCT03562156","phase":"PHASE3","title":"A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","status":"COMPLETED","sponsor":"Mycovia Pharmaceuticals Inc.","startDate":"2018-08-16","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":438},{"nctId":"NCT03561701","phase":"PHASE3","title":"A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","status":"COMPLETED","sponsor":"Mycovia Pharmaceuticals Inc.","startDate":"2018-08-23","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":425},{"nctId":"NCT07044947","phase":"","title":"Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2025-08-10","conditions":"Vulvovaginal Candidiasis","enrollment":3000},{"nctId":"NCT03840616","phase":"PHASE3","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","status":"COMPLETED","sponsor":"Mycovia Pharmaceuticals Inc.","startDate":"2019-03-13","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oteseconazole (VT-1161)","genericName":"Oteseconazole (VT-1161)","companyName":"Mycovia Pharmaceuticals Inc.","companyId":"mycovia-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oteseconazole is a selective inhibitor of fungal lanosterol 14α-demethylase (CYP51) that disrupts ergosterol synthesis in fungal cell membranes. Used for Vulvovaginal candidiasis, Oral candidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}